🇺🇸 FDA

Intelligence · Patent portfolio

NORTHWEST BIOTHERAPEUTICS Patents

Full USPTO pharma patent portfolio for NORTHWEST BIOTHERAPEUTICS — grant dates, expiration, and drug cross-links.

Patents
595
Expiring ≤24m
13

Quick answer

NORTHWEST BIOTHERAPEUTICS has 595 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 13 expire within 24 months — use filters for patent-cliff planning.

Page 8 of 13

  1. US 9636374

    pH-sensitive polymer-drug conjugates for targeted delivery of therapeutics

    Expires Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9637597

    DOPA-melanin formation in high ionic strength solutions

    Expires Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9623124

    Multimodal diagnostic technology for early stage cancer lesions

    Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9617541

    Biocompatible infinite coordination polymer nanoparticle-nucleic acid conjugates for antisense gene regulation

    Expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9616113

    Peptide conjugated particles

    Expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9615758

    Contribution of oxidative stress to AF electrograms

    Expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9603820

    Ornithine aminotransferase inhibition with GABA analogues for treatment of hepatocellular carcinoma

    Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9605054

    Composition and method for treating a tauopathy

    Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9593145

    Secondary structure stabilized NMDA receptor modulators and uses thereof

    Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9593069

    Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis

    Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9586890

    Screening methods for the binding affinity of chemical entities to biological molecules and NEDD4-1 inhibitors identified by the screening methods

    Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9585975

    MRI contrast agents

    Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9580400

    Cannabinergic nitrate esters and related analogs

    Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9572910

    pH responsive self-healing hydrogels formed by boronate-catechol complexation

    Expires Mon Feb 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9566355

    Bacteria-targeted magnetic resonance contrast agents

    Expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9566294

    Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis

    Expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9556232

    Anti-angiogenic molecules, nanostructures and uses thereof

    Expires Mon Jan 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9533947

    Benzamide compounds and related methods of use

    Expires Mon Dec 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9532948

    Nanostructure suitable for sequestering cholesterol and other molecules

    Expires Mon Dec 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9527819

    Pyridazine compounds, compositions and methods

    Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9522180

    Peptide conjugated particles

    Expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9517275

    Targeted therapy for the prevention of restenosis in the cardiovascular system

    Expires Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9517233

    Local cochlear application of statins for stimulating neurite regrowth in the cochlea

    Expires Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9512133

    NMDA receptor modulators and uses thereof

    Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9506056

    Nucleic acid functionalized nanoparticles for therapeutic applications

    Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9499494

    Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis

    Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9486540

    Methods for delivery to the central nervous system of nucleic acid nanoparticles to treat central nervous system disorders

    Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9474716

    SiRNA phospholipid conjugate

    Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9463186

    Treatment for dopaminergic disorders

    Expires Mon Oct 06 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9428467

    Selective calcium channel antagonists

    Expires Mon Aug 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9408845

    Formulations containing pyridazine compounds

    Expires Mon Aug 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9376690

    Templated nanoconjugates

    Expires Mon Jun 23 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9371277

    Benzamide compounds and related methods of use

    Expires Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9340576

    Methods of treating depression and other related diseases

    Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9340792

    Recombinant Lactobacillus with decreased lipoteichoic acid to reduce inflammatory responses

    Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9320719

    Multifunctional metal nanoparticles having a polydopamine-based surface and methods of making and using the same

    Expires Mon Apr 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9301927

    Para-xylene films and therapeutic uses thereof

    Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9301940

    Methods for screening antimicrobial and antiviral compounds and uses thereof

    Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9271962

    Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors

    Expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9259473

    Polymer hydrogel adhesives formed with multiple crosslinking mechanisms at physiologic pH

    Expires Mon Feb 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9248175

    Live-attenuated compositions for bacterial infections

    Expires Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9241928

    Antimicrobial compounds

    Expires Mon Jan 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9238811

    siRNA phospholipid conjugate

    Expires Mon Jan 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9216155

    Synthetic nanostructures including nucleic acids and/or other entities

    Expires Mon Dec 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9207243

    Use of GLUT4 inhibitors and DNA damaging agents for treating multiple myeloma

    Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9198948

    Methods of treating depression and other related diseases

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9181577

    Treatment of chronic pelvic pain syndrome

    Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9173897

    Molecular targets for ALS and related disorders

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does NORTHWEST BIOTHERAPEUTICS have?

595 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do NORTHWEST BIOTHERAPEUTICS patents expire?

13 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.